Publications by authors named "Hans Cruz"

Claim this Profile
C
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, John Radford, Kami Maddocks, Hans G Cruz

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Marie Toukam, Joseph P Boni, Mehdi Hamadani, Paolo F Caimi, Hans G Cruz

Cancer Chemother Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
Marie Toukam, Jens Wuerthner, Karin Havenith, Mehdi Hamadani, Paolo F Caimi, Hans G Cruz

Cancer Chemother Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Mehdi Hamadani, Graham P Collins, Paolo F Caimi, Felipe Samaniego, Alexander Spira, Hans G Cruz

Lancet Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Aaron D Goldberg, Ehab Atallah, David Rizzieri, Roland B Walter, Ki-Young Chung, Hans G Cruz

Leuk Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.
Anna K Stalder, Dominik Lott, Daniel S Strasser, Hans G Cruz, Andreas Krause

Br J Clin Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Priska Kaufmann, Hans G Cruz, Andreas Krause, Ivan Ulč, Atef Halabi

Br J Clin Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.
Jasper Dingemanse, Martine Gehin, Hans Gabriel Cruz, Petra Hoever

Drug Des Devel Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
Hans G Cruz, Justin L Hay, Petra Hoever, Federica Alessi, Erik T te Beek

Eur Neuropsychopharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.
Jasper Dingemanse, Hans Gabriel Cruz, Martine Gehin, Petra Hoever

J Pharm Sci· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
Hans G Cruz, Petra Hoever, Bijan Chakraborty, Kerri Schoedel, Edward M Sellers

CNS Drugs· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the cell type-specific ablation of the cAMP-responsive transcription factor in noradrenergic neurons on locus coeruleus firing and withdrawal behavior after chronic exposure to morphine.
Rosanna Parlato, Hans Cruz, Christiane Otto, Patricia Murtra, Jan Rodriguez Parkitna

J Neurochem· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice.
Hans G Cruz, Frédérique Berton, Monica Sollini, Christophe Blanchet, Marco Pravetoni

J Neurosci· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area.
Gwenaël Labouèbe, Marta Lomazzi, Hans G Cruz, Cyril Creton, Rafael Luján

Nat Neurosci· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applications of two-photon microscopy in the neurosciences.
Hans G Cruz, Christian Lüscher

Front Biosci· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal structural rearrangement of the cytoplasmic pore during activation of the 5-HT3A receptor.
Sandip Panicker, Hans Cruz, Christine Arrabit, Ka Fai Suen, Paul A Slesinger

J Biol Chem· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system.
Hans G Cruz, Tatiana Ivanova, Marie-Louise Lunn, Markus Stoffel, Paul A Slesinger

Nat Neurosci· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for a centrally located gate in the pore of a serotonin-gated ion channel.
Sandip Panicker, Hans Cruz, Christine Arrabit, Paul A Slesinger

J Neurosci· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis